Latest Production News

Netwealth Group Limited has reported a stellar FY25 with record funds under administration net flows of $15.8 billion and a 31% rise in EBITDA, underpinned by strong adviser growth and strategic technology investments.

Netwealth Group Limited reported a standout FY2025 with net profit rising nearly 40% and funds under administration climbing 28%, underpinning a 37.5% increase in dividends. Strategic fintech acquisitions and robust governance enhancements position the company for sustained growth.

Megaport Limited delivered a robust FY25 with 20% growth in annual recurring revenue and EBITDA surpassing guidance, setting the stage for continued expansion in FY26.

Megaport Limited reported a 16% revenue increase to $227.1 million in FY25, alongside a 20% rise in Annual Recurring Revenue, while posting a slight net loss of $0.3 million. The company expanded its global footprint and launched innovative new services, setting the stage for continued growth in FY26.

EQT Holdings Limited reported a robust FY25 with a 60% jump in net profit and record funds under management, while completing a major acquisition integration and raising dividends.

Ridley Corporation reported solid FY25 results with EBITDA up 8.6% to $97.8 million and NPAT rising 8.7% to $43.3 million, underpinned by strategic acquisitions and disciplined capital management.

Sipa Resources has completed a key heritage survey at its Crown Gold Project near Kalgoorlie, clearing the way for initial drilling expected to begin next month. Meanwhile, assay results from its maiden drilling in South Australia are imminent.

Pengana International Equities is set to diversify its portfolio by adding global private credit exposure, aiming to increase earnings and fully franked dividends by 56%, with monthly payments starting November 2025.

Redox Limited reported a 9.4% increase in FY25 revenue to $1.244 billion driven by volume growth and strategic acquisitions, while profits declined amid inflationary pressures. The company declared a final dividend of 6.5 cents per share and maintains zero net debt.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase in H1 2025, driven by strong sales of its precision medicine products and strategic acquisitions. The company is advancing multiple late-stage clinical trials and expanding its global manufacturing footprint.

Redox Ltd reported a robust 9.4% increase in revenue for FY25, supported by strong volume growth and three strategic acquisitions, despite margin compression and a challenging macroeconomic backdrop.

Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial growth and strategic investments, while advancing key clinical trials and maintaining full-year guidance.